Inflammasome activation contributes to cisplatin resistance in ovarian cancer
Josiany Carlos de Souza, Tatiana Massariol Pimenta, Bárbara da Silva Martins, José Matheus Simões Padilha, Solenny Maria Silva Butzene, Milleny Ganho Marçal, Leticia Batista Azevedo Rangel · 2025
Read Inflammasome activation contributes to cisplatin resistance in ovarian cancer by Josiany Carlos de Souza, Tatiana Massariol Pimenta, Bárbara da Silva Martins, José Matheus Simões Padilha, Solenny Maria Silva Butzene, Milleny Ganho Marçal, Leticia Batista Azevedo Rangel (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12699907.txt.
Description
Josiany de Souza and co-authors study drug resistance in ovarian cancer in 2025. The cancer often returns and stops responding to a key drug, cisplatin. The team asks whether a cell alarm system that drives swelling and cell death helps cause that resistance.
They tested three cell lines with rising resistance to the drug. Resistant cells released more alarm signals and showed more pore formation and burst cell death. A blocker of a key enzyme in that system cut cell movement when paired with the drug. The authors link the alarm system to resistance and suggest it as a target for new care.
Catalog record
| CREATOR | Josiany Carlos de Souza, Tatiana Massariol Pimenta, Bárbara da Silva Martins, José Matheus Simões Padilha, Solenny Maria Silva Butzene, Milleny Ganho Marçal, Leticia Batista Azevedo Rangel |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |